SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it will make any new features approved for the t:slim X2™ Insulin Pump by the U.S. Food and Drug Administration (FDA) in 2018 available to all in-warranty users at no cost through the Tandem Device Updater.1 Tandem and continuous glucose monitoring partner, Dexcom, Inc., also announced the extension of their existing joint welcome program for Animas customers from December 31, 2017 to March 31, 2018, matching the expiration date of Dexcom’s program to that of Tandem’s Touch Simplicity Today pump access program.

“Our commitment to offer t:slim X2 customers all new functionality approved by the FDA in 2018 for no additional cost underscores our goal to simplify the lives of people with diabetes by using software updates, rather than hardware replacements, to provide rapid access to new innovations,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “The tools necessary for diabetes management can be costly, and today’s announcement is evidence of our vision to use technology to remove a major barrier that may delay people from receiving all of the potential benefits of pump therapy through access to the latest available features.”

Tandem is the only company with a tool for providing remote software updates for its insulin pumps as new features are approved by the FDA. The Company successfully demonstrated its market-differentiating Tandem Device Updater by providing CGM integration to thousands of t:slim X2 customers for no cost following the FDA’s approval of the t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM integration in August 2017. 2 t:slim X2 Pump users were able to update their pumps from home using their personal computer. Any new features approved by the FDA for the t:slim X2 Pump in 2018 will be made available to all in-warranty t:slim X2 Pump users at no cost through the Tandem Device Updater.

Tandem and Dexcom Expand Existing Welcome Offers for Animas Customers

Tandem and Dexcom are now extending the terms of their welcome programs for Animas customers through March 31, 2018, to allow more Animas users access to the only CGM-integrated insulin pump approved to make treatment decisions without fingersticks.3

Dexcom Extends Existing t:slim X2 Welcome Program to March 31, 2018

Animas customers who purchase a t:slim X2 Insulin Pump can get started with a new Dexcom G5 Mobile CGM and receive a $200 reward card for taking a patient survey. The eligibility period for this program has been extended for Tandem customers from late 2017 to March 31, 2018.

“We are excited to be able to extend this program so that more Animas customers who are considering a t:slim X2 Pump can take advantage of this opportunity to start on a new Dexcom G5 Mobile CGM system at the same time,” said Steve Pacelli, Executive Vice President of Strategy and Corporate Development at Dexcom. “Tandem’s t:slim X2 Pump is now the only pump that integrates with our G5 Mobile CGM, and is a great option for Animas customers who chose their pumps for Dexcom integration. We hope this program extension helps make things easier for these Animas customers who are currently weighing their available pump options.”

Tandem’s Touch Simplicity Today Pump Access Program for Animas Customers

For a limited time, Animas pump users with warranties expiring on or before September 30, 2019 can use a Tandem insulin pump for the remainder of their warranty. The offer can be used for up to 24 months, for a refundable deposit of $999, which can be applied to the purchase of a new Tandem pump and/or supplies at the end of their current Animas warranty. The customer can choose to return the pump in the first 60 days of the program for a full refund of their deposit, or during the first nine months for a pro-rated refund based on the length of time they were in possession of the pump. This offer is available to eligible Animas customers through March 31, 2018.

“We believe the t:slim X2 Pump with Dexcom G5 Mobile CGM integration offers the simplest, most comfortable transition option for Animas customers, particularly for those who have only ever used an Animas pump,” said Mr. Blickenstaff. “Not only is the t:slim X2 Pump approved for use by children as young as six years old, it is also the only pump that is integrated with the CGM brand Animas users already know and love, which allows for CGM data to be shared with loved ones and caregivers via a mobile device.4”

Additional information on Tandem and Dexcom welcome programs available for Animas customers can be found at www.tandemdiabetes.com/animas.

About the t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM Integration

The t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration is the first sensor-augmented insulin pump approved to let users make treatment decisions without pricking their finger.3 It is the only available pump that conveniently displays a user’s insulin delivery activity and Dexcom G5 Mobile CGM data together on a single device. It is also the only insulin pump capable of remote software updates, allowing existing users to add features like CGM integration from home. It is up to 38% smaller than other pumps, but includes advanced features like a large color touchscreen, Bluetooth® radio, rechargeable battery, USB connectivity, and a 300-unit insulin capacity.

For additional product and safety information, visit www.tandemdiabetes.com/tslimX2info or call (877) 801-6901, Monday – Friday between 6am and 5pm Pacific Time

Free t:slim X2 Pump Demo on Your Mobile Device

Download Tandem’s free t:simulator™ App to experience the touchscreen interface of the t:slim X2 Pump with Dexcom G5 Mobile CGM integration directly on your mobile device. For more information and to download the app, visit http://www.tandemdiabetes.com/tsimulator.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2™ Insulin Pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, #tflex, #tconnect, and $TNDM.

Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.

Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Tandem Diabetes Care and t:flex are registered trademarks, and t:slim X2 and t:simulator are trademarks of Tandem Diabetes Care, Inc. Dexcom and Dexcom G5 are registered trademarks of Dexcom, Inc. All other trademarks are the property of their respective owners.

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding the Company’s plans to make any new t:slim X2 Pump feature releases approved by the U.S. Food and Drug Administration (FDA) in 2018 available to all in-warranty users at no cost through the Tandem Device Updater, the Company’s plan to offer the Touch Simplicity Today Pump Access Program and Dexcom’s continued offer of a welcome program to new t:slim X2 customers. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including the Company’s ability to complete the development and obtain required FDA approvals to offer future feature releases using the Tandem Device Updater and the Company’s inability to influence Dexcom’s administration of the welcome program to new t:slim X2 customers. Other risks and uncertainties are identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

_________________________________

1 Additional feature updates are not currently available for the t:slim X2 Pump with Dexcom G5 CGM integration and are subject to future FDA approvals. A prescription and additional training may be required to access certain future software updates. Offer only available to customers in the United States.

2 Dexcom G5 Mobile CGM sold separately. CGM coverage may vary based on insurance. Please consult your CGM supplier for coverage information. The Dexcom G5 Mobile CGM transmitter can only be paired with one medical device (either a Dexcom receiver or t:slim X2 Pump) and one consumer device (phone or tablet) at the same time.

3 CGM-based treatment requires fingersticks for calibration; may result in hypoglycemia if calibration not performed, when taking acetaminophen, or if symptoms/expectations do not match CGM readings.

4 Following your shared data requires the Dexcom Follow app.